Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases

Lynn G Feun, Y. Y. Lee, C. Plager, N. Papadopoulos, Niramol Savaraj, C. Charnsangavej, R. S. Benjamin, S. Wallace

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30%) had objective improvement in CT scans and three patients (13%) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.

Original languageEnglish
Pages (from-to)448-451
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number5
StatePublished - Jan 1 1990

Fingerprint

Cisplatin
Melanoma
Central Nervous System
Neoplasm Metastasis
Drug Therapy
Tomography
Radiotherapy
Carmustine
Bleomycin
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases. / Feun, Lynn G; Lee, Y. Y.; Plager, C.; Papadopoulos, N.; Savaraj, Niramol; Charnsangavej, C.; Benjamin, R. S.; Wallace, S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 5, 01.01.1990, p. 448-451.

Research output: Contribution to journalArticle

Feun, Lynn G ; Lee, Y. Y. ; Plager, C. ; Papadopoulos, N. ; Savaraj, Niramol ; Charnsangavej, C. ; Benjamin, R. S. ; Wallace, S. / Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 5. pp. 448-451.
@article{be95ca5052f244bcb0c6e66d79175cc1,
title = "Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases",
abstract = "Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30{\%}) had objective improvement in CT scans and three patients (13{\%}) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.",
author = "Feun, {Lynn G} and Lee, {Y. Y.} and C. Plager and N. Papadopoulos and Niramol Savaraj and C. Charnsangavej and Benjamin, {R. S.} and S. Wallace",
year = "1990",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "448--451",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases

AU - Feun, Lynn G

AU - Lee, Y. Y.

AU - Plager, C.

AU - Papadopoulos, N.

AU - Savaraj, Niramol

AU - Charnsangavej, C.

AU - Benjamin, R. S.

AU - Wallace, S.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30%) had objective improvement in CT scans and three patients (13%) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.

AB - Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30%) had objective improvement in CT scans and three patients (13%) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.

UR - http://www.scopus.com/inward/record.url?scp=0025091706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025091706&partnerID=8YFLogxK

M3 - Article

C2 - 1699402

AN - SCOPUS:0025091706

VL - 13

SP - 448

EP - 451

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -